Alphabet's AI drug discovery platform, Isomorphic Labs, has secured $600 million in funding from Thrive Capital. The investment aims to enhance the development of innovative therapies using advanced artificial intelligence techniques. This funding round highlights the growing intersection of AI and biotechnology in revolutionizing drug discovery processes.